New vaccine combo aims to extend life in deadly brain cancer
NCT ID NCT07347210
First seen Jan 19, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study tests whether adding a cancer vaccine (UCPVax) with or without an immunotherapy drug (pembrolizumab) to standard treatment can help people with a fast-growing type of glioblastoma live longer. About 98 adults with newly diagnosed, unmethylated MGMT glioblastoma will take part. The goal is to see if the vaccine boosts the immune system to fight the tumor better than standard care alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU La Timone
Marseille, France
Contact
Contact
-
CHU de Besançon
Besançon, France
Contact
Contact
-
Centre Georges François Leclerc
Dijon, France
Contact
Contact
-
Hôpital Saint-Louis - APHP
Paris, France
Contact
Contact
Conditions
Explore the condition pages connected to this study.